Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Business

INVITATION TO THE ANNUAL GENERAL MEETING OF BIOTIE THERAPIES CORP.


Print article Print article
Copyright © Thomson Reuters 2013. All rights reserved.
2013-02-28 08:16:24 -

BIOTIE THERAPIES CORP.       STOCK EXCHANGE RELEASE              28 February
2013 at 9.05 a.m.

INVITATION TO THE ANNUAL GENERAL MEETING OF BIOTIE THERAPIES CORP.

Notice is given to the shareholders of Biotie Therapies Corp. to the Annual
General Meeting to be held on Thursday, 4 April 2013 at 10 a.m. (Finnish time)
in an auditorium at the Mauno Koivisto Centre, address BioCity, Tykistökatu 6,
Turku, Finland. The reception of shareholders who have registered for the
meeting and the distribution of voting tickets will commence at 9.30 a.m.
(Finnish time).

A. MATTERS ON THE AGENDA OF THE ANNUAL GENERAL MEETING

At the Annual General Meeting, the following matters will be considered:

1. Opening of the meeting

2. Calling the meeting to order

3. Election of persons to 
confirm the minutes and to supervise the counting of votes 4. Recording the legality of the meeting 5. Recording the attendance at the meeting and adoption of the list of votes 6. Presentation of the financial statements, the report of the Board of Directors and the auditor's report for the year 2012 - Review by the CEO - The company's equity is less than a half of the share capital, if the capital loans are not counted among the items of the company's shareholders' equity. Possible measures to remedy the financial position of the company. 7. Adoption of the financial statements 8. Booking of the loss of the financial year The Board of Directors proposes that the loss of the financial year 2012 shall be transferred to the unrestricted equity and no dividend shall be distributed. 9. Resolution on the discharge of the members of the Board of Directors and the Managing Director from liability 10. Resolution on the remuneration of the members of the Board of Directors The Board of Directors proposes on the basis of the recommendation of the Nomination and Remuneration Committee that the remuneration payable to the members of the Board of Directors would be as follows: EUR 4,000 per month for the Chairman and EUR 3,000 per month for other Board members. In addition, it is proposed that reasonable travel expenses in connection with meetings would be compensated. 11. Resolution on the number of members of the Board of Directors The Board of Directors proposes on the basis of the recommendation of the Nomination and Remuneration Committee that the number of members of the Board of Directors would be six (6). 12. Election of members of the Board of Directors The Board of Directors proposes on the basis of the recommendation of the Nomination and Remuneration Committee that the following current members of the Board would be re-elected as members of the Board of Directors for the term expiring at the end of the following Annual General Meeting: Peter Fellner, William M. Burns, Merja Karhapää, Bernd Kastler, Ismail Kola and Guido Magni. 13. Resolution on the remuneration of the auditors The Board of Directors proposes on the basis of the recommendation of the Audit Committee that the auditors' fees would be paid pursuant to a reasonable invoice. 14. Election of the auditors The Board of Directors proposes on the basis of the recommendation of the Audit Committee that PricewaterhouseCoopers Oy, authorised public accountants, and Mr. Janne Rajalahti, Authorised Public Accountant, would be re-elected as the auditors of the company. 15. Authorising the Board of Directors to decide on the issuance of shares as well as the issuance of options and other rights entitling to shares The Board of Directors proposes that the Annual General Meeting would authorise the Board of Directors to resolve on one or more issuances which contains the right to issue new shares or dispose of the shares in the possession of the company and to issue options or other rights entitling to shares pursuant to chapter 10 of the Finnish Companies Act. The authorisation would consist of up to 95,000,000 shares in the aggregate. The authorisation would not exclude the Board of Directors' right to decide on a directed issue. The authorisation is proposed to be used for material arrangements from the company's point of view, such as financing or implementing business arrangements or investments or for other such purposes determined by the Board of Directors in which case a weighty financial reason for issuing shares, options or other rights and possibly directing a share issue would exist. The Board of Directors would be authorised to resolve on all other terms and conditions of the issuance of shares, options and other rights entitling to shares as referred to in chapter 10 of the Finnish Companies Act, including the payment period, grounds for the determination of the subscription price and subscription price or allocation of shares, option or other rights free of charge or that the subscription price may be paid besides in cash also by other assets either partially or entirely. The authorisation would be effective until 30 June 2014. The Board of Directors proposes that the authorisation would supersede earlier authorisations. 16. Closing of the meeting B. DOCUMENTS OF THE ANNUAL GENERAL MEETING The proposals relating to the agenda of the Annual General Meeting as well as this notice are available on Biotie Therapies Corp.'s website at www.biotie.com. In addition, Biotie Therapies Corp.'s financial statements, the report of the Board of Directors and the auditor's report are available on the above-mentioned website at the latest on 14 March 2013. The proposals of the Board of Directors and the financial statements are also available at the meeting. Copies of these documents and of this notice will be sent to shareholders upon request. The minutes of the meeting will be available on the above-mentioned website as of 18 April 2013. C. INSTRUCTIONS FOR THE PARTICIPANTS IN THE ANNUAL GENERAL MEETING 1. The right to participate and registration Each shareholder, who is registered on 21 March 2013 in the shareholders' register of the company held by Euroclear Finland Ltd, has the right to participate in the Annual General Meeting. A shareholder, whose shares are registered on his or her personal Finnish book-entry account, is registered in the shareholders' register of the company. A shareholder registered in the shareholders' register of the company, who wants to participate in the Annual General Meeting, shall register for the meeting by giving a prior notice of participation during a period from 1 March 2013 to 28 March 2013 at 4.00 p.m. (Finnish time) by which time the notice needs to have arrived. Such notice can be given: a) through the company's website www.biotie.com; b) by e-mail to virve.nurmi@biotie.com; c) by telephone +358 2 274 8911; or d) by regular mail to Biotie Therapies Corp. / Virve Nurmi, Tykistökatu 6, FI- 20520 Turku, Finland. In connection with the registration, the shareholder shall notify his or her name, personal identification number, address, telephone number and the name of a possible assistant or proxy representative and the personal identification number of a proxy representative. The personal data given to Biotie Therapies Corp. is used only in connection with the Annual General Meeting and with the processing of related registrations. A shareholder who is present at the Annual General Meeting has the right to request information with respect to the matters to be considered at the meeting pursuant to chapter 5, section 25 of the Finnish Companies Act. 2. Advance voting A shareholder, who has a Finnish book-entry account, may vote in advance on certain items of the agenda of the Annual General Meeting through the company's website from 1 March 2013 to 28 March 2013 at 4.00 p.m. (Finnish time). Unless a shareholder voting in advance will be present in person or by proxy in the Annual General Meeting, he or she cannot use his or her right under the Finnish Companies Act to request information or otherwise use his or her right to be heard at the meeting, or request a vote. If certain agenda items or decision proposals have changed after the beginning of the advance voting period, the possibility of a shareholder voting in advance to vote on such item may be restricted, unless he or she will be present in person or by proxy in the Annual General Meeting. The terms and conditions and other instructions relating to the electronic advance voting may be found on the company's website www.biotie.com. The Finnish book-entry account number of the shareholder is needed for voting in advance. 3. Proxy representative and powers of attorney A shareholder may participate in the Annual General Meeting and exercise his or her rights at the meeting by way of proxy representation. A proxy representative shall produce a dated proxy document or otherwise in a reliable manner demonstrate his or her right to represent the shareholder at the Annual General Meeting. When a shareholder participates in the Annual General Meeting by means of several proxy representatives representing the shareholder with shares at different securities accounts, the shares by which each proxy representative represents the shareholder shall be identified in connection with the registration for the Annual General Meeting. Possible proxy documents should be delivered in original to the company, address Biotie Therapies Corp. / Virve Nurmi, Tykistökatu 6, FI-20520 Turku, Finland, before the last date for registration. 4. Holders of nominee registered shares A holder of nominee registered shares has the right to participate in the Annual General Meeting by virtue of such shares, based on which he or she on the record date of the Annual General Meeting, 21 March 2013, would be entitled to be registered in the shareholders' register of the company held by Euroclear Finland Ltd. The right to participate in the General Meeting requires, in addition, that the shareholder on the basis of such shares has been temporarily registered in the shareholders' register held by Euroclear Finland Ltd at the latest on 28 March 2013 by 10.00 a.m. (Finnish time). Such temporary registration constitutes a due registration for the Annual General Meeting. A holder of nominee registered shares is advised to request without delay from his or her custodian bank necessary instructions regarding the temporary registration in the shareholders' register of the company, the issuing of proxy documents and the registration for the Annual General Meeting. The account management organization of the custodian bank has to register the holder of nominee registered shares, who wants to participate in the Annual General Meeting, to be temporarily entered into the shareholders' register of the company at the latest on 28 March 2013 by 10.00 a.m. (Finnish time). 5. Other information On the date of this notice to the Annual General Meeting, 28 February 2013, the total number of shares and votes in Biotie Therapies Corp. is 452,710,738. Of these shares, 8,348,247 are owned by Biotie Therapies Corp. and its subsidiaries. In Turku, 28 February 2013 Biotie Therapies Corp. Board of Directors For further information, please contact: Virve Nurmi, Investor Relations Manager tel. +358 2 274 8900, e-mail: virve.nurmi@biotie.com DISTRIBUTION: NASDAQ OMX Helsinki Ltd Main Media This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Biotie Therapies Oyj via Thomson Reuters ONE [HUG#1681720]


Press Information:




Contact Person:


Disclaimer: © 2014 Thomson Reuters. The press releases or report contained herein is protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Thomson Reuters's, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com